Could this become the first cannabis-derived prescription drug in the U.S.?
CBD-focused Epidiolex reduced convulsive seizures significantly among epilepsy patients in new clinical trial, says drug’s maker. But will the FDA approve its sale in the U.S.?
Experimental marijuana-based drug Epidiolex significantly reduced convulsive seizures among epilepsy patients in a recent clinical trial, according to GW Pharmaceuticals, the U.K. company that makes the drug.
Among the drug’s primary ingredients is cannabidiol, better known as CBD, a non-psychoactive marijuana derivative that is anecdotally known for helping some patients suffering from epilepsy, Crohn’s and other diseases. There is little scientific evidence backing up patients’ experiences with CBD, which is one of the reasons GW Pharmaceuticals’ first-of-its-kind study is so important.
Epidiolex is being studied to treat Dravet syndrome, a rare type of epilepsy for which there are currently no treatments approved in the U.S. GW Pharmaceuticals is currently in talks with federal regulators, hoping that Epidiolex will be introduced to the U.S. market — which would make it the first prescription drug in America that is extracted from cannabis.
Don’t forget to like WeedTV @yourweedtv